Ann: Results of Meeting, page-25

Roth helped them raise approx 24million back at end of 2019 to purchase a new lead drug, which is about to enter the clinic.

There is a OTC offering, but am unsure if this existed prior to this placement or not.

But the share really started to gain traction when Roth issued a detailed analysis coverage for 13cents, when share were hovering around 5cents on 1st October 2020.

I personally believe that Joel and the BOD have picked the right brokers and they will do wonders for Incannex in the next few months.